Ceftaroline Fosamil in the Treatment of Community-Acquired Bacterial Pneumonia and Acute Bacterial Skin and Skin Structure Infections

被引:43
|
作者
Lodise, Thomas P. [1 ]
Low, Donald E. [2 ]
机构
[1] Albany Coll Pharm & Hlth Sci, Albany, NY 12208 USA
[2] Mt Sinai Hosp, Univ Hlth Network, Toronto, ON M5G 1X5, Canada
关键词
RESISTANT STAPHYLOCOCCUS-AUREUS; IN-VITRO ACTIVITY; CLARITHROMYCIN EXTENDED-RELEASE; BROAD-SPECTRUM CEPHALOSPORIN; PENICILLIN-BINDING PROTEINS; VANCOMYCIN PLUS AZTREONAM; HUMAN SIMULATED EXPOSURES; GRAM-NEGATIVE PATHOGENS; METHICILLIN-RESISTANT; COMPLICATED SKIN;
D O I
10.2165/11635660-000000000-00000
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Ceftaroline fosamil is a cephalosporin antibacterial approved by the US Food and Drug Administration (FDA) for use in the treatment of acute bacterial skin and skin structure infections (ABSSSI) and community-acquired bacterial pneumonia (CABP). After intravenous administration, ceftaroline fosamil is rapidly converted to its bioactive metabolite, ceftaroline. Ceftaroline has broad-spectrum in vitro activity against Gram-positive and Gram-negative bacteria, including contemporary resistant Gram-positive phenotypes, such as methicillin-resistant Staphylococcus aureus (MRSA) and multidrug-resistant Streptococcus pneumoniae. Because of its unique spectrum of activity, the Clinical and Laboratory Standards Institute (CLSI) designated ceftaroline as a member of a new subclass of B-lactam antimicrobials, cephalosporins with anti-MRSA activity. The activity of ceftaroline against S. aureus extends to heteroresistant vancomycin-intermediate, vancomycin-intermediate, vancomycin-resistant and daptomycin-nonsusceptible isolates. Ceftaroline has low minimum inhibitory concentrations (MICs) for all tested species of streptococci, and has potent activity against S. pneumoniae isolates with varying degrees of penicillin resistance. The activity of ceftaroline is limited against Enterococcus faecalis and Enterococcus faecium and against anaerobes such as Bacteroides fragilis. The in vitro activity of ceftaroline includes many Gram-negative pathogens, but does not extend to bacteria that produce extended-spectrum beta-lactamases, class B metallo-beta-lactamases or AmpC cephalosporinases, or to most nonfermentative Gram-negative bacilli. Ceftaroline fosamil has been studied for the treatment of complicated skin and skin structure infections (cSSSI) and community-acquired pneumonia (CAP) in phase III randomized, double-blind, international, multicentre noninferiority clinical trials. Two identical trials (CANVAS 1 and CANVAS 2) compared the efficacy of ceftaroline fosamil with that of vancomycin plus aztreonam in 1378 adults with cSSSI. Results demonstrated that ceftaroline was noninferior to vancomycin plus aztreonam, with 91.6% in the ceftaroline fosamil group (pooled analysis) achieving clinical response compared with 92.7% in the vancomycin plus aztreonam group (difference -1.1%, 95% CI -4.2, 2.0). An additional analysis evaluated clinical cure in a subgroup of patients who met the FDA guidance definition of ABSSSI at treatment day 3. Clinical response, defined as cessation of lesion spread and absence of fever, was 74.0% in the ceftaroline fosamil group compared with 66.2% in the vancomycin plus aztreonam group (treatment difference 7.8%, 95% CI 1.3, 14.0). Clinical efficacy of ceftaroline fosamil in 1240 hospitalized adults with CAP was compared with that of ceftriaxone in two additional phase III trials (FOCUS I and FOCUS 2). Of note, because ceftriaxone does not have activity against MRSA, patients with confirmed or suspected MRSA CAP were excluded from the FOCUS trials. Results demonstrated that ceftaroline was noninferior to ceftriaxone, with 84.3% in the ceftaroline fosamil group achieving clinical cure compared with 77.7% in the ceftriaxone group (difference 6.7%, 95% CI 1.6, 11.8). An additional analysis of the trials was conducted in patients with moderate to severe CAP and at least one proven typical bacterial pathogen at baseline (i.e. CABP). Day 4 clinical response rates were 69.5% for ceftaroline and 59.4% for ceftriaxone (difference 10.1%, 95% CI -0.6, 20.6). In the phase III trials, adverse event rates were similar between groups. Overall, ceftaroline is well tolerated, which is consistent with the good safety and tolerability profile of the cephalosporin class. In summary, ceftaroline fosamil is a broad-spectrum parenteral cephalosporin with excellent in vitro activity against resistant Gram-positive pathogens, including MRSA, as well as many common Gram-negative organisms. It is a welcome treatment option for ABSSSI and CABP.
引用
收藏
页码:1473 / 1493
页数:21
相关论文
共 50 条
  • [41] Ceftaroline fosamil use in hospitalized patients with acute bacterial skin and skin structure infections: Budget impact analysis from a hospital perspective
    Huang, Xingyue
    Beresford, Eric
    Lodise, Thomas
    Friedland, H. David
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2013, 70 (12) : 1057 - 1064
  • [42] Serious community infections - Acute bacterial community-acquired pneumonia in adults
    Berdyev, D.
    Scapin, R.
    Labille, C.
    Lambin, L.
    Fartoukh, M.
    REANIMATION, 2011, 20 (02): : S566 - S575
  • [43] Clinical Efficacy of Patients With Secondary Bacteremia Treated With Omadacycline: Results From Phase 3 Acute Bacterial Skin and Skin Structure Infections and Community-Acquired Bacterial Pneumonia Studies
    Sakoulas, George
    Eckburg, Paul B.
    Amodio-Groton, Maria
    Manley, Amy
    Tzanis, Evan
    Das, Anita F.
    Noble, Robert
    McGovern, Paul C.
    OPEN FORUM INFECTIOUS DISEASES, 2021, 8 (06):
  • [44] Real-world effectiveness of omadacycline and impact of unapproved omadacycline prescription claims among adult outpatients with community-acquired bacterial pneumonia or acute bacterial skin and skin structure infections
    Lodise, Thomas P.
    Gunter, Kyle
    Mu, Fan
    Gao, Emily
    Yang, Danni
    Yim, Erica
    Sandor, Steve
    Berman, Gail
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2023, 29 (08): : 952 - 964
  • [45] Ceftaroline fosamil as a potential treatment option for Staphylococcus aureus community-acquired pneumonia in adults
    Welte, Tobias
    Kantecki, Michal
    Stone, Gregory G.
    Hammond, Jennifer
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2019, 54 (04) : 410 - 422
  • [46] Economic analysis of ceftaroline fosamil for treating community-acquired pneumonia in Spain
    Torres, Antoni
    Bassetti, Matteo
    Welte, Tobias
    Rivolo, Simone
    Remak, Edit
    Peral, Carmen
    Charbonneau, Claudie
    Hammond, Jennifer
    Ansari, Wajeeha
    Grau, Santiago
    JOURNAL OF MEDICAL ECONOMICS, 2020, 23 (02) : 148 - 155
  • [47] Dalbavancin for the treatment of acute bacterial skin and skin structure infections
    Ramdeen, Sheena
    Boucher, Helen W.
    EXPERT OPINION ON PHARMACOTHERAPY, 2015, 16 (13) : 2073 - 2081
  • [48] Tedizolid for treatment of acute bacterial skin and skin structure infections
    Ye Hui
    Lu Xiaoju
    EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, 2015, 13 (09) : 1051 - 1060
  • [49] Delafloxacin for the Treatment of Acute Bacterial Skin and Skin Structure Infections
    Lee, Young Ran
    Burton, Caitlin Elizabeth
    Bevel, Kolton Rucks
    JOURNAL OF PHARMACY TECHNOLOGY, 2019, 35 (03) : 110 - 118
  • [50] Antibiotic treatment of acute bacterial skin and skin structure infections
    Russo, Alessandro
    Vena, Antonio
    Bassetti, Matteo
    CURRENT OPINION IN INFECTIOUS DISEASES, 2022, 35 (02) : 120 - 127